Lipoprotein(A) Concentrations In Rheumatoid Arthritis On Biologic Therapy: Results From The Cardiovascular In Rheumatology [Carma] Study Project
EstadísticasView Usage Statistics
Full recordShow full item record
AuthorGarcía Gómez, Carmen; Martín Martínez, Maria A.; Castañeda, Santos; Sanchez Alonso, Fernando; Uriarte Ecenarro, Miren; González Juanatey, Carlos; Romera Baures, Montserrat; Santos Rey, José; Pinto Tasende, José Antonio; Quesada Masachs, Estefanía; Tornero Molina, Jesús; Martínez González, Olga; Cobo Ibáñez, Tatiana; Chamizo Carmona, Eugenio; Manrique Arija, Sara; Fábregas Canales, Dolores; Díaz González, Federico; Llorca Díaz, Francisco Javier; González-Gay Mantecón, Miguel Ángel
Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved.
The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics.
Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors.
Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (?: ?0.303, 95% confidence interval: ?0.558 to ?0.047; P = .02).
RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.
Enlace a la publicación
Collections to which it belong
- D22 Artículos